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Clinical studies have suggested a potential involvement of endothe-lial dysfunction and damage in the development and severity ofacute graft-versus-host disease (aGvHD). Accordingly, we found
an increased percentage of apoptotic caspase 3 positive blood vessels in
duodenal and colonic mucosa biopsies of patients with severe aGvHD.
In murine experimental aGvHD, we detected severe microstructural
endothelial damage and reduced endothelial pericyte coverage accompa-
nied by reduced expression of endothelial tight junction proteins leading
to increased endothelial leakage in aGvHD target organs. During intes-
tinal aGvHD, colonic vasculature structurally changed, reflected by
increased vessel branching and vessel diameter. As recent data demon-
strated an association of endothelium-related factors and steroid refrac-
tory aGvHD (SR-aGvHD), we analyzed human biopsies and murine tis-
sues from SR-aGvHD. We found extensive tissue damage but low levels
of alloreactive T-cell infiltration in target organs, providing the rationale
for T-cell independent SR-aGvHD treatment strategies. Consequently,
we tested the endothelium-protective PDE5 inhibitor sildenafil, which
reduced apoptosis and improved metabolic activity of endothelial cells in
vitro. Accordingly, sildenafil treatment improved survival and reduced
target organ damage during experimental SR-aGvHD. Our results
demonstrate extensive damage, structural changes, and dysfunction of
the vasculature during aGvHD. Therapeutic intervention by endotheli-
um-protecting agents is an attractive approach for SR-aGvHD comple-
menting current anti-inflammatory treatment options. 
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Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only cur-
ative treatment option for many patients suffering from hematological malignan-
cies. A major complication of allo-HSCT is acute graft-versus-host disease
(aGvHD), an inflammatory condition primarily affecting the skin, liver, and intes-
tines. aGvHD occurs in more than two thirds of patients undergoing allo-HSCT.1
Steroid treatment is successful in most of these patients
(75%-80%). However, the 20%-25% of patients who fail
initial treatment with steroids (steroid-refractory aGvHD
[SR-aGvHD]) have very high mortality.2,3 No standard
treatment for SR-aGvHD is currently available, and its
pathobiology is poorly understood, thereby hindering the
development of novel therapeutic approaches.
The endothelium is the first contact for immunological
effector cells in the blood and a key regulator in various
inflammatory processes. In early complications after allo-
HSCT such as transplantation-associated-microangiopa-
thy,4 veno-occlusive disease,5 capillary leak syndrome6
and diffuse alveolar hemorrhage7 the endothelium was
shown to be relevant. Recent studies also suggest a criti-
cal role of the endothelium in aGvHD. Angiogenesis
appears to be a very early event during aGvHD, occurring
before immune cell infiltration in target organs.8 During
later phases of aGvHD, endothelial apoptosis has been
described in cutaneous aGvHD.9,10 Clinical studies
demonstrated that soluble markers of endothelial damage
such as von Willebrand factor,11 thrombomodulin,12-14
micro particles released by endothelial cells (EC)15 as well
as the CD40/CD40 ligand axis,16 can be used as biomark-
ers during aGvHD. Furthermore, factors of endothelial
damage were correlated with the mortality rate of
patients suffering from SR-aGvHD.12,13,17 In addition to
endothelial pathology in the microvasculature, arterial
vessels were described to suffer from endothelial damage
during aGvHD with consequences for their physiological
properties.18
The characterization of endothelial function during
aGvHD and SR-aGvHD is still incomplete and effective
pharmacologic strategies aiming at the normalization of
endothelial dysfunction to ameliorate aGvHD and SR-
aGvHD are lacking.
Methods
Patient material and histology of human biopsies
Collection of human samples was approved by the institu-
tional ethics committees of Charité Berlin and Medical
University Hannover and was in accordance with the
Declaration of Helsinki. From the Charité cohort, we included
intestinal biopsies with aGvHD versus no aGvHD after allo-
HSCT performed between 2007 and 2015. We identified 12 duo-
denal and 11 colon biopsies from patients with aGvHD grade III-
IV. As a control, we used 19 duodenal and ten colon biopsies
from allo-HSCT recipients without histological evidence of
aGvHD.19 From the Hannover cohort colon biopsies from 11
patients with aGvHD were included. From each patient, biop-
sies were taken at two time points: at diagnosis of aGvHD and
later at diagnosis of SR-aGvHD. Detailed clinical data from both
cohorts are given in the Online Supplementary Tables S1, S2, S4
and S6.
Mice and acute graft-versus-host disease experiments
aGVHD models were used as described previously.8,20,21
Control groups (no aGvHD) were transplanted with the same
bone marrow (BM) cell numbers and T-cell numbers from syn-
geneic donors. In order to mimic SR-aGvHD, we used the
chemotherapy based murine models 129→B6 major histocom-
patibility complex (MHC)-matched and B6→B6D2F1 (hap-
loidentical) and the radiation based murine model BALB/c→B6
MHC-mismatch with conditioning and cell dosages analogue to
the models described above. Recipient mice were treated
intraperitoneal with 0.5 mg/kg/day dexamethasone beginning at
day+4 after HSCT (Merck, Darmstadt, Germany).22,23 We used
dexamethasone because of its longer lasting effects compared to
methyl-prednisolone or prednisolone enabling once daily dosing
in the murine models. The rationale for starting at day+4 is that
during this time leukocytes start to infiltrate target organs during
aGvHD.8,21,24 Clinical scores, weight loss and survival in the B6-
BDF SR-aGVHD model are given in the Online Supplementary
Figure S1.
Histology of murine tissues
Tissue samples were cryoembedded and scored as previously
described.19
Evans blue assay
For assessment of endothelial leakage, Evans blue assay was
performed as described in detail elsewhere.25
Immunolabeling against VE-cadherin for light sheet 
fluorescence microscopy
25 mg/mouse anti-VE-cadherin antibody (Thermo
Scientific, eBioBV13-eFluor660) was intravenously (i.v.)
injected in mice from B6→BDF aGvHD model. Mice
were sacrificed and perfused with phosphate buffered
saline (PBS) followed by 4% paraformaldehyde in PBS.
Sample preparation and imaging of whole organs were
performed by light sheet fluorescence microscopy as pre-
viously described.26 Analysis of vasculature and its seg-
mentation was performed using Imaris 8.1 software
(Bitplane, Concord, MA, USA). Branch level was deter-
mined by branching point and diameter changes of the
vasculature.27
Hepatic endothelial cell isolation
Single cell suspensions were generated via digestion with 2
mg/mL collagenase D and 5 mL deoxyribonuclease. Hepatic EC
cell fraction was enriched by gradient centrifugation using 30%
histodenz (Sigma Aldrich). For gene expression analysis, the
obtained single cell suspension was further enriched for EC
(CD11b-, CD45dim/-, CD31+) by flow cytometry using a Bio-Rad
S3 cell Sorter. EC purity was determined via flow cytometry
analysis of ICAM1+ and CD31+ cells.
Statistics
Survival data were analyzed using the Kaplan–Meier method
and compared with the Mantel–Cox log-rank test. For statistical
analysis of all other data, Student’s t-test was used, unless indi-
cated otherwise. Values are presented as mean ± standard error
of the mean (SEM). Values of P ≤ 0.05 were considered statisti-
cally significant. All statistical analyses were performed using
GraphPad Prism software (GraphPad Software Inc., La Jolla, CA,
USA).
Additional experimental procedures are described in the
Online Supplementary Appendix.
Results
Endothelial apoptosis during severe intestinal acute
graft-versus-host disease in human biopsies
We stained colon and duodenum biopsies from allo-
HSCT recipients with the apoptotic cell marker caspase 3
(Casp3). We found that Casp3 positive (Casp+) EC were
rare events in biopsies of allo-HSCT recipients without
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aGvHD. In contrast, Casp3+ EC were frequent in intestin-
al biopsies of patients diagnosed for grade III-IV aGvHD.
Figure 1 shows exemplary pictures of colon sections in
human allo-HSCT recipients without aGvHD (Figure 1A)
versus grade III-IV intestinal aGvHD (Figure 1B).
Quantification revealed a significant increase in percent-
age of Casp3+ vessels in duodenal (Figure 1C) and colonic
mucosa (Figure 1D) of grade III-IV aGvHD. Patient char-
acteristics and clinical data are given in the Online
Supplementary Table S1 (for Figure 1C) and the Online
Supplementary Table S2 (for Figure 1D). Our data demon-
strate endothelial apoptosis during severe intestinal
aGvHD in human allo-HSCT recipients.
Micro-structural endothelial changes during 
experimental acute graft-versus-host disease 
in transmission electron microscopy 
In order to further investigate micro-structural changes
of the endothelium we used experimental aGvHD mod-
els. We first performed transmission electron microscopy
(TEM) of liver (Figure 2A to F) and colon (Online
Supplementary Figure S2A to F) at day+15 after allo-HSCT.
We found that the hepatic sinusoidal endothelium in allo-
HSCT recipients without aGvHD is not affected. The
endothelial monolayer as well as the EC-cell contacts
were intact (Figure 2A and B), and we observed a normal
endothelial monolayer in hepatic sinusoids (Figure 2B). In
contrast, the hepatic sinusoidal endothelium during
aGvHD was severely damaged with close immune cell-
EC interactions (Figure 2C). Furthermore, we observed a
discontinuous endothelial monolayer at the EC-immune
cell contact zone during hepatic aGvHD (Figure 2D). In
addition, we found blistering of the endothelial monolay-
er (Figure 2E) as well as platelet adhesion on the sinu-
soidal endothelial monolayer (Figure 2E) and in the blis-
tered endothelium (Figure 2F) during hepatic aGvHD. In
colonic mucosa, vessels were again normal in allo-HSCT
recipients without aGvHD (Online Supplementary Figure
S2A to F). The endothelial monolayer was well-struc-
tured, smooth and surrounded by pericytes (Online
Supplementary Figure S2A) with intact tight junctions
(Online Supplementary Figure S2B). In contrast, during
intestinal aGvHD the endothelial monolayer was ruffled
(Online Supplementary Figure S2C) with perivascular fib-
rinogen deposits (Online Supplementary Figure S2A, C, D
and F). Endothelial cytoplasm was enriched with vesicles
aGvHD impact on endothelium
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Figure 1. Endothelial damage in human intestinal biopsies. (A) Exemplary picture of a colon biopsy of a patient after allogeneic hematopoietic stem cell transplan-
tation (allo-HSCT) without histologic evidence of acute graft-versus-host disease (aGvHD) and low level of endothelial apoptosis. The white dotted lines indicate ves-
sel lumen and the arrow indicates one apoptotic caspase 3 positive (Casp3+) endothelial cell. (B) Exemplary picture of a colon biopsy of a patient with grade III-IV
intestinal aGvHD and increased endothelial apoptosis. The white dotted lines indicate vessel lumen and the arrows indicate apoptotic Casp3+ endothelial cells. (C)
Quantification of Casp3+ events in duodenal endothelium of allo-HSCT recipients given in percent of vessels in high-power fields (HPF). (D) Quantification of Casp3+
events in colonic endothelium of allo-HSCT recipients given in percent of vessels in HPF. Percentage of Casp3+ vessels was tested for significance by Student’s t-test
(***P<0.001; n=7-11 patients per group). Error bars indicate mean ± standard error of the mean. 
A B
C D
and the endothelial monolayer was disrupted (Online
Supplementary Figure S2D and E). During intestinal
aGvHD, clotting was present in the colonic microvascula-
ture as well as convolution of the endothelial monolayer
(Online Supplementary Figure S2E). In conclusion, TEM
revealed an extensive endothelial damage in target organs
during aGvHD. 
Pericyte coverage, tight junctions and endothelial 
leakiness during acute graft-versus-host disease
As a method to quantify endothelial damage in exper-
imental aGvHD, we analyzed pericyte-coverage of
CD31+ vessels in the colon and liver by fluorescence
microscopy. Representative pictures are shown in Figure
3A and G. We found reduced pericyte-coverage of ves-
sels in hepatic sinusoids (Figure 3B) and in colonic
mucosa (Figure 3H) during aGvHD, indicating a dam-
aged endothelial monolayer. In order to address the
question whether the endothelial barrier function is
altered during aGvHD, we assessed the endothelial
expression of the tight junction protein ZO-1 and the
intercellular junction protein VE-cadherin in vessels of
aGvHD target organs a shown in the representative pic-
tures in Figure 3C and I. Immunostaining revealed
reduced endothelial ZO-1 abundance during aGvHD,
which correlates with reduced numbers of intact tight
junction (Figure 3D and J). Moreover, colonic microvas-
cular and hepatic sinusoidal endothelium VE-cadherin
abundance was reduced (Figure 3E and K).
In order to investigate, if the reduced expression of
tight junction and intercellular connection proteins of the
endothelium during aGvHD have functional conse-
quences in vivo, we injected Evans blue solution intra-
venously and analyzed the penetration into the organs.
In allo-HSCT recipients with aGvHD endothelial leakage
was significantly increased in liver (Figure 3F) and colon
(Figure 3L) as compared to HSCT recipients without
aGvHD. 
Next, we were interested if the detected endothelial
changes occurred exclusively in the target organs during
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Figure 2. Visualization of acute graft-versus-host dis-
ease-associated ultrastructural changes in the liver
by transmission electron microscopy. Representative
pictures of sections from liver taken at day+15 after
experimental hematopoietic stem cell transplantation
(HSCT) in the chemotherapy based B6→BDF model.
(A and B) Liver sinusoidal endothelial monolayer after
syngeneic-HSCT (syn-HSCT) without acute graft-ver-
sus-host disease (aGvHD). (A) Normal, fenestrated
sinusoidal blood vessel completely covered with
endothelial monolayer. (B) Higher magnification of a
100 nm large fenestration of the endothelium in the
liver. (C to-F) Sinusoidal liver endothelial monolayer
after allo-HSCT during aGvHD. (C) Liver sinusoidal
vessel with destroyed and unregularly shaped
endothelial monolayer in contact with an immune
cell. (D) Higher magnification of contact zone
between immune cell and endothelial cell. (E)
Blistering of the endothelial monolayer with a platelet
in the region of injury. (F) Higher magnification of
endothelial blistering. The perivascular space is
marked by a red triangle. V: vessel lumen; EM:
endothelial monolayer; F: fenestrated endothelium;
IC: immune cell; E: erythrocyte; P: platelet; red circle:
loss of endothelium; red triangle: endothelial blister-
ing. Control groups (no aGvHD) were transplanted
with the same bone marrow cell numbers and T-cell
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Figure 3. Pericyte coverage, tight junctions and endothelial leakiness during acute graft-versus-host disease. Organs were harvested at day+15 after experimental
hematopoietic stem cell transplantation (HSCT) in the chemotherapy based LP/J→B6 model. Control groups (no acute graft-versus-host disease [aGvHD]) were trans-
planted with the same bone marrow cell numbers and T-cell numbers from syngeneic donors.  (A, B, and G to H) Quantification of pericyte coverage of vessels. (A and
G) Representative pictures of staining for pericyte marker α smooth muscle actin (αSMA) in red and endothelial cell marker CD31 in green. Right organs of animals with-
out aGvHD and left organs of animals suffering from aGvHD. (B and H) Ratio of αSMA positive area and CD31 positive area in (B) liver sinusoidal endothelium and (H)
in colonic mucosal vessels in aGvHD versus no aGvHD. (C, D, I and J) Quantification of endothelial tight junction protein expression ZO-1. (C and I) Representative pic-
tures of staining ZO-1 in green and CD31 in red. Right organs of animals without aGvHD and left organs of animals suffering from aGvHD. (D and J) Percentage of ZO-
1+ CD31+ area in (D) liver sinusoidal endothelium and (J) colonic mucosal vessels in aGvHD versus no aGvHD. (E and K) Quantification of endothelial adherence junction
protein expression VE-cadherin. Percentage of VE-cadherin positive area in (E) liver sinusoidal endothelium and (K) colonic mucosal vessels in aGvHD versus no aGvHD.
(F and L) Measurement of Evans blue extravasation in ng Evans blue per mg at day+15 after experimental allo-HSCT in the chemotherapy based B6→BDF model. (F)
Liver and (L) colon of aGvHD versus no aGvHD. Significance was tested with Student’s t-test (*P<0.05; **P<0.01; n=5 animals per group). All experiments were repro-













aGvHD or if this is a systemic effect. We therefore ana-
lyzed endothelial leakage in the kidney and skeletal mus-
cle, which are typically not affected in human aGvHD.
We have previously confirmed these organs to be unaf-
fected by aGvHD in our models.8,21 The Evans blue assay
revealed no significant changes of endothelial leakage in
these non-target organs during aGvHD (Online
Supplementary Figure 3A and B) suggesting that increased
endothelial leakiness predominantly occurs in aGvHD
target organs. 
Taken together, we found disturbed endothelial tight
junctions and intercellular connections leading to
increased vascular leakiness in target organs of aGvHD. 
Structural changes of vasculature in target organs 
during aGvHD
In order to get a better overview of the three-dimen-
sional (3D) changes of the vasculature, we compared
aGvHD and non-GvHD colonic vessel structure and
organization with light sheet fluorescence microscopy
after in vivo perfusion with an anti-VE-cadherin antibody.
Figure 4A and C show normal VE-cadherin staining and
vessel branching in a 3D model in colon at d+15 after
HSCT without aGvHD. During aGvHD, we found con-
siderably different staining patterns for VE-cadherin
(Figure 4B) and increased vessel branching in colon
(Figure 4D). Using this 3D model to quantify vessel
branch levels of vasculature, we found significantly
increased total vessel branching in colonic vasculature
during aGVHD as compared to HSCT recipients without
aGvHD (Figure 4E). Accordingly, analysis of branching
levels from vessel segments (Figure 4F) and vessel diame-
ter (Figure 4G) revealed a significant increase during intes-
tinal aGvHD. We conclude that aGvHD is associated
with structural changes in colonic vasculature. 
Dysfunction of the macrovasculature during acute
graft-versus-host disease
As aGvHD is associated with severe signs of microvas-
cular dysfunction, we became interested if aGvHD also
influences the physiological functions of macrovascula-
ture as suggested previously.18 We examined vessel con-
traction and relaxation in mouse mesenteric arteries dur-
ing aGvHD versus no aGVHD after HSCT by myographic
measurements. We found that maximum contraction of
mesenteric arteries in response to high doses of noradren-
aline (NA) and phenylephrine (Phe) was not significantly
changed (Online Supplementary Figure S4A and B).
However, partial contraction at lower doses of NA and
Phe was moderately increased during aGvHD versus no
aGvHD (Online Supplementary Figure S4C and D). In addi-
tion, fractional relaxation after maximum contraction in
response to ACh was slower in arteries from allo-HSCT
recipients with aGvHD (Online Supplementary Figure S4E).
Taken together we found increased contraction and
reduced relaxation potential of mesenteric arteries during
aGvHD indicating systemic hypertension. 
Gene expression changes of endothelial cells during
acute graft-versus-host disease
In order to better understand the molecular pathways
involved in endothelial dysfunction during aGvHD we
performed gene array expression analysis of flow cytom-
etry sorted hepatic EC from HSCT recipients with
aGvHD versus without aGvHD at day+15. We found sig-
nificant endothelial gene expression changes in comple-
ment activation, apoptosis, oxidative damage, IL-1 sig-
naling and cell cycle during aGvHD (Online
Supplementary Figures S5, S6 and S7; Online Supplementary
Table S3). Furthermore, barrier function and cytoskeleton
pathways were differentially regulated, including expres-
sion changes of Rho GTPases (Online Supplementary Table
3). We performed interaction analysis of selected
endothelium-specific genes (Online Supplementary Figure
7) and found differential expression of Cdh1 and Cdh13
(coding for cadherins), Thbd (coding for thrombomod-
ulin), Vegfc (coding for vascular endothelial growth factor
c) and Anpgt1/2 (coding for angiopoietin 1 and 2). In sum-
mary, we detected endothelial gene expression changes
in different clinically relevant pathways during aGvHD
providing possible targets for future therapeutic inter-
ventions. 
Inflammatory activity and endothelial damage during
steroid-refractory acute graft-versus-host disease
Since recent clinical data has provided evidence on the
importance of endothelial pathology specifically in SR-
aGVHD,12,17,28-31 we decided to characterize both inflam-
matory infiltrates and endothelial damage in this setting.
Based on previous data,22 we first performed dose-finding
studies with steroids in different aGvHD models to estab-
lish a protocol with progressive aGvHD despite high dose
steroid treatment. Treatment with dexamethasone start-
ing at day+4 after allo-HSCT, showed progressive
aGvHD in our models (Online Supplementary Figure S1;
Figure 5).  
We analyzed vascular pericyte coverage as well as
infiltration by CD4+ donor T cells in dexamethasone-
treated SR-aGvHD versus untreated aGvHD at day+15
after allo-HSCT. We found reduced inflammatory T-cell
infiltrates in SR-aGvHD versus untreated aGvHD (Figure
5A to D). The predominant remaining cell population in
colon during SR-aGvHD were CD4+ and CD8+ T cells
(Figure 5 C and D) as well as CD11b+ and F4/80+ myeloid
cells (Online Supplementary Figure S8A and B). Endothelial
damage as quantified by pericyte coverage reduction in
colon vessels was equally severe in SR-aGvHD and
untreated aGvHD (Figure 5E). In order to connect the
experimental findings to the clinical context of SR-
aGvHD, we quantified leukocyte infiltration in intestinal
biopsies of patients at diagnosis of aGvHD and at later
time points of SR-aGvHD in two independent cohorts.
Figure panels 5F to J demonstrate significant lower infil-
tration of CD45+ leukocytes in colon biopsies as well as
duodenum biopsies (Figure 5I). The leukocyte reduction
was mainly due to significantly lower infiltration by
CD3+ T cells in colon biopsies (Figure 5K, L, M and O) as
well as duodenum biopsies (Figure 5N) during SR-
aGvHD versus aGvHD at time of diagnosis. Figure 5K
gives a typical example of colonic aGvHD at onset with
high levels of inflammatory infiltrates by CD3+ T cells
and Figure 5L a representative colonic section after
steroid treatment and diagnosis for SR-aGvHD, demon-
strating reduced inflammatory infiltrates. In addition, we
performed caspase 3 staining and demonstrated a high
level of endothelial apoptosis during aGvHD both at
diagnosis as well as during SR-aGVHD (Figure 5P). A
typical example of high inflammatory activity at aGvHD
diagnosis time point and low level of inflammatory
activity at diagnosis of SR-GvHD in combination with
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considerable tissue damage in hematoxylin and eosin
(H&E) staining is given in the Online Supplementary Figure
S8, panels C and D. Patient characteristics and clinical
information is given in the Online Supplementary Tables S4
to S6. Our data indicates that inflammatory activity in
intestinal tissues is reduced after steroid treatment, while
the endothelial damage is not influenced by steroid treat-
ment during SR-aGvHD. 
Endothelial protection by PDE5 inhibition in acute
graft-versus-host disease (aGvHD) and 
steroid-refractory aGvHD 
Based on our results demonstrating extensive endothe-
lial damage and reduced inflammatory T-cell infiltration
during SR-aGvHD, we hypothesized that pharmacologic
protection of the endothelium would have stronger pro-
tective effects on SR-aGvHD versus treatment of aGvHD
Figure 4. Structural changes of vasculature in tar-
get organs during acute graft-versus-host disease
by scanning light sheet fluorescence microscopy.
We analyzed organs at day+15 after experimental
hematopoietic stem cell transplantation (HSCT) in
the chemotherapy based B6→BDF model. Control
groups (no aGvHD) were transplanted with the
same bone marrow (BM) cell numbers and T-cell
numbers from syngeneic donors. (A and B) VE-cad-
herin signal of vasculature in colon of (A) allogene-
ic-HSCT (allo-HSCT) recipients without aGvHD and
(B) allo-HSCT recipients with aGvHD. (C-D)
Computed three-dimensional (3D) model of
colonic vasculature with number of branches
(blue= low branch levels; red= high branch levels)
of (C) allo-HSCT recipients without aGvHD and (D)
allo-HSCT recipients with aGvHD. (E to G) Analysis
of colonic vasculature parameters. Assessment of
(E) total number of branches (F) distribution of
vessels branching level and (G) vessel diameter
distribution in allo-HSCT recipients with aGvHD
versus without aGvHD. Significance of total num-
ber of branches was tested by Student’s t-test
(***P<0.001; n=3 animals per group) and signifi-
cance of vessel branching level was tested by two-
way ANOVA with Tukey’s multiple comparison test
(***P<0.001; n=3 animals per group). Error bars
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at its initiation stage. As a first example for such an
approach, we used the PDE5 inhibitor sildenafil, which
has been demonstrated to normalize endothelial dysfunc-
tion in vivo in different settings.32-39 First, we tested silde-
nafil in vitro for EC protection from cytotoxic damage,
mediated by etoposide. Sildenafil protected EC from
etoposide-induced reduction of endothelial metabolic
activity and proliferation (Figure 6A). Sildenafil signifi-
cantly reduced etoposide-induced endothelial apoptosis,
as quantified by Casp3+ staining (Figure 6B). For co-stim-
ulatory capacity, we checked CD86high expression of EC
by flow cytometry. Sildenafil treatment resulted in a sig-
nificant reduction of etoposide-induced CD86 expression
on EC (Figure 6C). Our data demonstrate a protective
effect of sildenafil on etoposide-induced endothelial dys-
function in vitro. 
We tested the effect of sildenafil in our experimental
models of aGvHD (Figure 7A to F) and SR-aGvHD (Figure
7G to L). In the aGvHD model without steroid treatment,
we found that sildenafil treatment had no significant effect
on survival (Figure 7A). However, sildenafil-treated allo-
HSCT recipients with aGvHD had significantly lower clin-
ical scores at different time points (Figure 7B) as well as
lower histopathological aGvHD scores in the liver (Figure
7C) and colon (Figure 7D) as compared to untreated allo-
HSCT recipients with aGvHD. In addition, we found a
non-significant trend towards reduced costimulatory
capacity and antigen presentation potential of hepatic EC
under sildenafil treatment (Figure 7E and F). The vascular
density (Online Supplementary Figure S9A) as well as the
density of lymphatic vessels was not significantly affected
by sildenafil treatment (Online Supplementary Figure S9B).
During SR-aGvHD, sildenafil treatment significantly
improved survival (Figure 7G). Due to high mortality,
clinical scoring was only significant in the early phase
(Figure 7H). Histopathological aGvHD scores in the iver
(Figure 7I) and colon (Figure 7J) were significantly reduced
in sildenafil-treated allo-HSCT recipients with SR-
aGvHD. Additionally, we found a trend towards reduced
co-stimulatory capacity as well as significantly reduced
antigen presentation potential of hepatic EC in sildenafil-
treated SR-aGvHD, demonstrated by lower MHC class I
and II expression (Figure 7K). We confirmed these find-
ings in another murine aGvHD model (129→B6, MHC-
matched, Online Supplementary Figure S10). We found
non-significant trends towards increased vascular density
(Online Supplementary Figure S9C) and lymphatic vascular
density in sildenafil-treated SR-GvHD versus controls
(Online Supplementary Figure S9D). Next, we analyzed the
effect of sildenafil on the endothelium during SR-aGvHD
with electron microscopy analyses of liver and colon tis-
sues (Figure 7M to P). We found endothelial damage in
the liver and colon in untreated and sildenafil-treated SR-
aGvHD. However, the sildenafil treated SR-aGvHD
group showed reduced endothelial ruptures in liver
(Figure 7N) and less prominent fibrinogen deposits in
colonic biopsies (Figure 7P).  
In order to analyze for effects of sildenafil on T-cell pro-
liferation, we performed in vivo proliferation assays with
carboxyfluorescein succinimidyl ester (CFSE) labeled allo-
geneic T cells. In irradiated mice, sildenafil had no signif-
icant effects on in vivo proliferation of allogeneic T cells
(Online Supplementary Figure S11A to C). We next ana-
lyzed and quantified the impact on sildenafil on immune
cell subsets in peripheral blood during SR-aGvHD and
found no significant differences (Online Supplementary
Figure S11D to M). Our data suggest that the observed
positive effect of sildenafil on SR-aGvHD is predominant-
ly mediated by its effect on EC as opposed to effects on
immune cells. 
Discussion
The standardized and well-described aGvHD mice
models provide the unique opportunity to experimentally
address the role of endothelial dysfunction after HSCT.
We found that severe endothelial damage, structural
changes of the vasculature and endothelial dysfunction
occur during aGvHD. Due to lack of suitable animal mod-
els, less detailed data is available for other important
endothelium-related complications of allo-HSCT, such as
veno-occlusive disease and transplantation-associated
microangiopathy. In line with the experimental results,
we found that endothelial damage is present in the colon
and duodenum of patients with severe aGvHD. This find-
Figure 6. Reduction of endothelial apoptosis and endothelial activation by sildenafil in vitro. Mouse cardiac endothelial cells (MCEC) were incubated with either
phosphate buffered saline (PBS)/ 0,1% dimethylsulfoxide (DMSO) (control  [ctr]), 100 nm etoposide (eto), an inducer of cell death, or with 100 nm etoposide and
34 nm sildenafil (eto+sil) for 24 hours before analysis. (A) MTT assay showed higher optical density of eto+sil group versus eto-only group. (B) Staining for apoptotic
cell marker caspase 3 (Casp3) showed reduced Casp3+ cells per high-power field (HPF) in eto+sil group compared to eto-only group. (C) Flow cytometry analysis of
CD86, a costimulatory and endothelial activation marker, showed reduced percentage of endothelial CD86high cells in eto+sil group compared to eto-only group.
Significance was tested by Student’s t-test (*P<0.05; n=2-3 experiments with at least triplicates per condition). Error bars indicate mean ± standard error of the
mean.
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ing is consistent with a previously published study,
demonstrating increased endothelial injury in human skin
biopsies during aGvHD.10 Additionally, a series of clinical
studies have collected supporting evidence on increased
endothelial dysfunction during aGvHD, such as high
numbers of circulating EC40-43 and elevated serum levels of
the endothelial stress markers ST2, von Willebrand factor,
angiopoietin 2 and thrombomodulin.31,44-46
We have previously shown that aGvHD is associated
with increased angiogenesis in target organs.8,47 In the cur-
rent study, we used light sheet fluorescence microscopy to
demonstrate that target organ aGvHD is associated with
vascular structural changes in terms of higher branching
levels and larger diameter of the vasculature. Taking into
account the available evidence from our previous studies
as well as the experiments from this manuscript, it
becomes clear that vascular destruction as well as patho-
logical angiogenesis occur in parallel in the early phase
during aGvHD in target organs. These processes finally
result in restructuring of the vasculature as visualized and
quantified in Figure 4. Interestingly, increased branching
levels of vasculature were first reported during pathologi-
cal angiogenesis in malignant tumors.48 This finding led to
the concept of ‘vascular normalization’ to improve anti-
tumor therapies.49 However, the significance of pathologi-
cal vascular organization with increased branching level
for the pathophysiology of aGvHD and possible therapeu-
tic implications remains to be determined. 
We found that the expression of tight junction- and
adherence junction proteins were reduced during
aGVHD, leading to increased vascular permeability in
aGvHD target organs after allo-HSCT. The role of tight
junction- and adherence junction proteins for vascular
barrier maintenance50-52 as well as leukocyte transmigra-
tion53,54 has been described previously. Additionally, the
promotion of the adherence junction protein VE-cadherin
in tumor vasculature increased T-cell infiltration into the
tumor.55 These findings may open a new window for
Figure 7. In vivo treatment of acute graft-versus-host disease (aGvHD) and steroid-refractory-aGvHD with sildenafil. (A to G) Treatment of aGvHD with 10 mg/kg/d
sildenafil after experimental allogeneic hematopoietic stem cell transplantation (allo-HSCT) at day+15 after experimental allo-HSCT in the radiation based
B6→BALB/c model. (A) Survival analysis and (B) clinical aGvHD manifestations of sildenafil (sil) treated allo-HSCT recipients with aGvHD versus control substance
phosphate buffered saline/dimethylsulfoxide (PBS/DMSO, control [ctr]) treated allo-HSCT recipients with aGvHD. Histopathological assessment of aGvHD manifes-
tations in (C) liver and (D) colon in sildenafil versus control substance treated allo-HSCT recipients at day+15. Flow cytometry quantification of (E) major histocom-
patibility complex I (MHCI) and MHCII expression and (F) CD80 and CD86 expression of isolated liver sinusoidal endothelial cells of sildenafil versus control substance
treated allo-HSCT recipients at day+15. (G to L) Treatment with 10 mg/kg/d sildenafil in a murine model of SR-aGvHD at day+15 after experimental allo-HSCT in the




aGvHD impact on endothelium
haematologica | 2021; 106(8) 2157
Figure 7. (G) Survival analysis and (H) clin-
ical aGvHD manifestations of sildenafil
(SR-aGvHD+sil) versus control substance
treated (SR-aGvHD+ctr) SR-aGvHD.
Histopathological assessment of aGvHD
severity in (I) liver and (J) colon in SR-
aGvHD+sil and SR-aGvHD+ctr at day+15
after allo-HSCT. Flow cytometry quantifi-
cation of (K) MHCI and MHCII expression
and (L) CD80 and CD86 expression of iso-
lated liver sinusoidal endothelial cells of
SR-aGvHD+sil and SR-aGvHD+ctr at
day+15 after allo-HSCT. Significance was
tested by Kaplan-Meier method and com-
pared with the Mantel-Cox log-rank test
(*P<0.05; n=8-10 animals per group) and
Student’s t-test (*P<0.05; **P<0.01;
n=6 animals per group). Error bars indi-
cate mean ± standard error of the mean.
Survival data was pooled from two experi-
ments. All experiments were reproduced
in a biological independent experiment
and shown are representative results of
one experiment. (M to P) Visualization of
SR-aGvHD and sildenafil treated SR-
aGvHD associated ultrastructural
changes in the liver and the colon by
transmission electron microscopy. Shown
are typical pictures of sections from liver
and colon taken at day+15 after experi-
mental allo-HSCT in the chemotherapy
based 129→B6 model. (M and N)
Sinusoidal liver endothelial monolayer
during SR-aGvHD and sildeanfil (sil) treat-
ed SR-aGvHD. (M) Liver sinusoidal vessel
of untreated SR-aGvHD with destroyed
and unregularly shaped endothelial
monolayer, marked by a red circle. (N)
Liver sinusoidal vessel of Sildenafil treat-
ed SR-aGvHD with small ruptures of the
endothelial monolayer, marked by a red
circle. (O and P) Colonic mucosa endothe-
lium during SR-aGvHD and sildeanfil
treated SR-aGvHD. (O) The vessel of
untreated SR-aGvHD is surrounded by
massive perivascular fibrinogen deposits
marked by a red rhombus. (P)
Occasionally little perivascular fibrinogen
deposits, marked by a red rhombus, could
be detected in sildenafil treated SR-
aGvHD. V: vessel lumen; E: erythrocyte; N:
nucleus; red rhombus: perivascular fib-
rinogen deposits; red circle: loss of
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aGvHD therapies aiming at reducing vascular permeabil-
ity and stabilization of vascular tight-junctions as well as
adherence-junctions. Vestweber and colleagues have gen-
erated mice with stabilized endothelial junctions; these
mice had strongly reduced neutrophil and lymphocyte
recruitment into inflamed tissues.56 Examples for a thera-
peutic approach derive from the field of sepsis where
reduction of vascular permeability with the αVb3 antag-
onist cilengitide57 or with an antibody binding to
angiopoietin 2 and TIE258 which led to substantial biolog-
ical benefits. 
Recent clinical studies suggest a role of endothelial
pathology particularly in SR-aGvHD13,14,17,28,29,31 and a high
medical need for development of respective therapies.
We now demonstrate in two independent clinical cohorts
as well as in experimental models that inflammatory infil-
tration in target organs is considerably reduced compared
to aGvHD at diagnosis. Consequently, we found that
dexamethasone treatment did not significantly reduce the
severity of endothelial damage during SR-aGvHD. Pavan
Reddy’s group recently published the results of extensive
experiments in murine models of SR-GvHD. In line with
our findings, their results point towards the existence of
T-cell independent mechanisms in the pathophysiology
of SR-GvHD.23 This may explain the historically disap-
pointing clinical results of immunosuppressive treatments
for SR-aGvHD. The low inflammatory status in connec-
tion with considerable endothelial pathology provides a
rationale for therapies protecting the endothelium during
SR-aGvHD. Based on previous encouraging data on nor-
malization of endothelial dysfunction,32-39 we used the
PDE5 inhibitor sildenafil as a first attempt to treat SR-
aGvHD by an ‘endothelium-protective’ approach.
Sildenafil treatment ameliorated aGvHD and the effect
was more pronounced in case of SR-aGvHD compared
with previously untreated aGvHD. The latter observation
may be explained by the high level of tissue inflammation
in non-glucocorticoid treated aGvHD mice superimpos-
ing the beneficial effects of sildenafil on EC. However, we
cannot exclude the possibility of a synergistic effect of
sildenafil with steroids in our models. 
The direct mechanisms of sildenafil treatment on the
course of SR-aGvHD remain unclear. However, improve-
ment of vascular barrier function and reduction of EC
apoptosis probably contribute to the beneficial effects of
sildenafil. During aGvHD we found increased vascular
permeability in target organs and alterations of Rho
GTPases, who are critical regulators of endothelial barrier
function.59 Sildenafil-mediated stabilization of endothelial
barrier function60,61 as well as impact of sildenafil on regu-
lation of Rho GTPases62 have been described previously.
We found that apoptosis and expression of relevant genes,
such as nitric oxide synthase (Nos3) and BCL-2, was
increased in target organ EC during aGvHD. Sildenafil has
been shown to have cyto-protective effects by regulation
of nitric oxide synthase 3 signaling and BCL-2 expres-
sion.63 In addition, sildenafil may have positive effects by
stabilizing vessel surrounding pericytes and thereby vas-
cular integrity: PDE5 targets cGMP, which has been
demonstrated to inhibit the proliferation of smooth mus-
cle cells by causing a delay in G1/S transition in the cell
cycle.64 Interestingly, we detected differentially regulated
cell cycle genes in EC during aGvHD. Of note, we found
that sildenafil treatment led to reduction of aGvHD-asso-
ciated expression of co-stimulatory molecules on target
organ EC. However, our finding that sildenafil had no sig-
nificant effects on in vivo proliferation of allogeneic donor
T cells in irradiated hosts argue against the biologic signif-
icance of the observed impact of sildenafil on EC co-stim-
ulatory molecule expression during aGvHD. 
In conclusion, our results demonstrate extensive dam-
age, structural changes, and dysfunction of the vascula-
ture during aGvHD, and our findings suggest a novel con-
cept of therapeutic intervention by endothelium-protect-
ing agents as an attractive treatment approach for SR-
aGvHD. A likely future perspective is to test endotheli-
um-targeting approaches complementing treatment
options with proven efficacy in SR-aGvHD, such as JAK-
2 inhibition.65
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